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Abstract
Background: Brominated flame retardants (BFRs) are endocrine disruptors that bioaccumulate in the placenta, but
it remains unclear if they disrupt tissue thyroid hormone (TH) metabolism. Our primary goal was to investigate
associations between placental BFRs, TH levels, Type 3 deiodinase (DIO3) activity and TH sulfotransferase (SULT)
activities.
Methods: Placenta samples collected from 95 women who delivered term (>37 weeks) infants in Durham, NC, USA
(enrolled 2010–2011) were analyzed for polybrominated diphenyl ethers (PBDEs), 2,4,6-tribromophenol (2,4,6-TBP),
THs (T4, T3 and rT3), and DIO3 and TH SULT activities.
Results: PBDEs and 2,4,6-TBP were detected in all placenta samples. PBDEs were higher in placental tissues from
male infants compared to female infants, with 2,4,6-TBP and BDE-209 levels approximately twice as high. Among
male infants, placental BDE-99 and BDE-209 were negatively associated with rT3 placental levels. For female infants,
placental BDE-99 and 2,4,6-TBP were positively associated with T3 concentrations. DIO3 activity was also
significantly higher in placental tissues from male infants compared to females, while 3,3’-T2 SULT activity was
significantly higher in placental tissues from females compared to males. Among males, several PBDE congeners
were positively correlated with T3 SULT, while BDE-99 was negatively associated with T3 SULT among females.
Associations generally remained after adjustment for potential confounding by maternal age and gestational
age at delivery.
Conclusions: These results suggest BFRs accumulate in the placenta and potentially alter TH function in a sex-
specific manner, a possible mechanism to explain the sex-dependent impacts of environmental exposure on
children’s growth and development. More research is needed to elucidate the effects of BFRs on placenta function
during pregnancy, as well as the biological consequences of exposure and thyroid disruption.
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Background
Brominated flame retardants (BFRs) such as polybromi-
nated diphenyl ethers (PBDEs) and 2,4,6-tribromophenol
(2,4,6-TBP) have been applied to numerous types of
furniture and electronic items in order to meet state and
federal flammability standards [1]. PBDE mixtures were
phased out of use and production because of their
persistence, bioaccumulation, and potential toxicity be-
ginning in 2004 [2, 3]. Despite their phase out, many
older products containing PBDEs remain in use in the
home environment, suggesting human exposure to
PBDEs will continue for some time. 2,4,6-TBP is an
intermediate in the production of other BFRs and also
has been used as a reactive flame retardant. In addition,
2,4,6-TBP is currently used as fungicide/wood preser-
vative. Although less is known about 2,4,6-TBP, data
indicate that human exposure is ubiquitous and, like
PBDE exposure, ongoing [4, 5].
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PBDEs and 2,4,6-TBP have similar chemical structures
(i.e. the presence of a hydroxyl group and halogens on
an aromatic ring) to thyroid hormones (THs) leading to
concerns about their potential impact on TH regulation,
an important process with numerous down-stream
health impacts. Indeed, several studies demonstrate that
PBDEs and 2,4,6-TBP disrupt hormone regulation in
birds, rodents, and fish [6–9] and epidemiological stud-
ies indicate that PBDE exposure impacts thyroid hor-
mone regulation [10]. Proposed mechanisms of TH
dysfunction include disruption of TH serum transporters
such as transthyretin (TTR) and thyroid-binding globu-
lin (TBG) via the displacement of endogenous THs,
aberrant binding to TH nuclear receptors, or disruption
of TH-metabolizing enzymes such as deiodinases (DIO)
and sulfotransferases (SULT) [11–18], but these effects
may be tissue specific, and remain to be fully elucidated.
THs are known to be particularly important for fetal
growth and development [19]. During pregnancy, the
placenta facilitates the uptake of THs from maternal
circulation and subsequent delivery to the fetal compart-
ment, particularly during the first trimester, when the fetus
relies solely on maternally-derived THs [20]. TH delivery to
target cells involves numerous active and passive transport
pathways, but is regulated in part by the activity of TH
metabolizing enzymes in the placenta. In our previous in
vitro work, we demonstrated that the activities of TH-
metabolizing enzymes (e.g. DIO and SULT) are inhibited
by exposure to PBDEs, 2,4,6-TBP and other halogenated
compounds [11, 12], suggesting that they may impact pla-
cental TH concentrations and fetal TH delivery. Deiodinase
type 3 (DIO3) in particular is highly expressed in the
placenta, and its primary function is to convert thyroxine
(T4) to the genomically inactive hormone, reverse triiodo-
thyronine (rT3). This action serves to both buffer the levels
of T4 reaching the fetus, and also provide a source of iodine
to the fetus [21, 22]. While BFRs have been detected in
human placenta samples previously (e.g. [23–25]), the
clinical significance of these measures, and their potential
importance in thyroid hormone regulation have not, to our
knowledge, been evaluated.
The primary goal of this study was to examine associa-
tions between BFRs (PBDEs and 2,4,6-TBP), TH concen-
trations, and measures of TH metabolic enzyme activity
in human placental tissues. Based on our previous work
in pooled hepatic microsomes, we hypothesized that
BFR exposure may be associated with decreased TH en-
zyme function (e.g. DIO3) which may result in increased
(e.g. T4) or decreased (e.g. rT3) TH levels in placental
tissues. Such changes may be important for understand-
ing life-long health risks of exposure to PBDEs and
2,4,6-TBP, particularly as the disruption of TH regulation
can lead to effects that may manifest later in life as
cognitive and behavioral deficits and altered growth [19].
Methods
Study population
Participants were recruited within a prospective cohort
study assessing the joint effect of social, environmental,
and host factors on pregnancy outcomes (the Healthy
Pregnancy, Healthy Baby (HPHB) Study). The HPHB
study enrolled pregnant women from the Duke Obstet-
rics Clinic and the Durham County Health Department
Prenatal Clinic [26–28]. Our analyses included a subset
of women from the HPHB study who were seen at the
latter clinic, delivered at the Duke University Medical
Center between March 2010 and December 2011, and
from whom sufficient placenta tissue was available for
this study (n = 102). Because we anticipated that gestational
age may be related to TH concentrations in placenta, we
further restricted analyses to women giving birth to term
infants (37 or more weeks gestation (n = 95)). Reflective of
the population of women receiving services at the clinic
used in recruitment, the HPHB cohort is predominantly
African-American with the majority of mothers having a
high school diploma or less education and few having
private health insurance [23]. All aspects of this study were
carried out in accordance with a human subjects research
protocol approved by the Duke University Institutional
Review Board and all women provided informed consent
prior to participation.
Placenta BFR and thyroid hormone analysis
Placenta tissue subsamples were taken at the time of
delivery at the Duke University Medical Center. Tissues
(approximately 5–20 g) were stored in screwtop cryovials
at −80 °C until analysis. BFR levels in these placental
tissues were previously described (see [23]) and methods
are therefore not reported here. All sample values were
blank subtracted and method detection limits (MDLs)
were calculated as three times the standard deviation of
the lab blank values for each analyte. TH levels were
measured using a modified method from our laboratory;
complete details on this method can be found in the
Additional file 1: Supplemental material [29, 30].
Preparation of placental microsomes/cytosol and
deiodinase/sulfotransferase activity assays
Preparation of placental microsomes and DIO3 assays
were performed using a modified method from our
laboratory [12, 30]. Preparation of placental cytosolic
fractions and SULT assays were performed using a
modified method from our laboratory [11]. A detailed
set of protocols are provided in the Additional file 1:
Supplemental material.
Quality control/Quality assurance
For QA/QC in the TH measurements, lab blanks were
run in each batch of placenta tissue sample extractions,
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and isotopically labeled internal standards were used in
all samples. All sample values were blank subtracted and
method detection limits (MDLs) were calculated as three
times the standard deviation of the lab blank values for
each analyte. All samples were run with 5 ng 13C-T3,
13C-rT3, and 13C-T4 as internal standards. The recovery
of the 13C-labeled THs were calculated for all tissue
samples and lab blanks in order to assess the recovery
efficacy of the extraction and clean-up methods (mean
blank recovery of THs is 101%; mean sample recovery of
THs is 75%).
For 3,3’-T2 SULT assays, all placenta cytosol samples
were analyzed in duplicate. For T3S SULT assays, each
batch of ten placenta cytosol samples included one
duplicate sample to assess assay precision.
Statistical analysis
Preliminary analyses (Shapiro-Wilkes Test) indicated
that TH, BFR, and enzyme activity data were not
normally distributed. Accordingly, non-parametric statis-
tical tests were used or data were log10 transformed
prior to statistical analyses. We used Spearman correl-
ation coefficients to assess associations between BFRs
and THs. To assess factors associated with placenta
BFRs and relationships between BFRs and THs, we used
linear regression models (continuous outcome measures
were log10-transformed). To aid in the interpretation of
regression results, we exponentiated beta coefficients
(10β), producing the multiplicative change in outcome. As
predictors of THs and enzyme activity, BFR levels were
categorized into tertiles in order to minimize the effect of
skewed data and outliers. Given the lower detection fre-
quency of BDE-209, data were dichotomized into those
with detectable levels of BDE-209 and non-detects. Re-
gression analyses were also adjusted a priori for maternal
age and gestational age at delivery, factors which we antic-
ipated might confound associations between BFRs and
THs. In addition, we considered potential confounding by
maternal pre-pregnancy BMI and race; however, the inclu-
sion of these variables did not impact regression coeffi-
cients (change of less than 10%) and they were not
included in the final adjustment set.
Increasingly the epidemiologic literature suggests
that prenatal exposure to environmental chemicals
impacts male and female infants differently. We hy-
pothesized that there may be important sex differences
in associations between BFRs, THs and enzyme activ-
ity. To explore these differences we conducted all
analyses in the full cohort (combined), as well as
stratified by infant sex. All sex-specific analyses were
conducted using n = 94 because the sex of the infant
was missing for one sample. Statistical analyses were
performed using SAS Version 9.2. A p-value of 0.05
was considered statistically significant.
Maternal serum
The primary focus of our work was to evaluate relation-
ships between placental BFRs, TH concentrations, and
measures of TH metabolic enzyme activity; however,
maternal 3rd trimester serum samples were previously
assessed for BFRs for a subsample of mother’s in our
current cohort (n = 80 matched pairs). Details of these
samples have been described previously in [31].
Although these data were not available for our full
cohort, we did evaluate relationships between maternal
serum BFR levels and placenta serum BFR measures
(Spearman correlations). In addition, we evaluated po-
tential differences in maternal serum BFR levels by
infant sex. Analyses were limited to BDE-47, BDE-100
and BDE-153 which were all detected in >70% of serum
samples. Other congeners were detected less frequently.
Within the subsample geometric means of these conge-
ners were 12.42 ng/g lipid for BDE-47, 2.64 ng/g lipid
for BDE-100, and 1.48 ng/g lipid for BDE-153.
Results
Population characteristics
Of the 95 women included in analyses, 68% were
non-Hispanic black, and 57% were under 25 years
old. This was the first pregnancy for 45.5% of the
women, and 43.6% of the women had completed
more than a high school education. Finally, less than
10% of the women had private health insurance. Add-
itional information on the demographics of this popu-
lation have been reported in [23].
Brominated flame retardants
Detailed information on the concentrations of the differ-
ent PBDE congeners and 2,4,6-TBP have been reported
previously [23]. Briefly, detection frequencies for BDE-
47, −100, −99, −154, −153, −209, and 2,4,6-TBP were
all > 50%. The most common PBDE measured was BDE-
47, representing 34% of ΣBDE burden. Generally, 2,4,6-
TBP was detected at higher concentrations than the
PBDEs; the geometric mean concentration of 2,4,6-TBP
was 15.4 ng/g lipid (range: 1.31–316 ng/g lipid), while
the geometric mean concentration of BDE-47 was
5.09 ng/g lipid (range: 0.12–141 ng/g lipid). Concentra-
tions were higher in placental tissues associated with
male infants compared to female infants (Fig. 1). For
example, BDE-209 and 2,4,6-TBP were approximately
twice as high in placental tissues associate with male
infants as compared to female infants (p <0.01). In sam-
ples for which we had paired maternal serum (n = 80),
there was no relationship between maternal serum BDE
concentrations and infant sex (serum BDE-47, p = 0.59;
BDE-100, p = 0.62; BDE-153, p = 0.72); despite their
being significant, or near significant, differences by sex
in placental BFRs concentrations in the subsample
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(placenta BDE-47, p = 0.06; BDE-100, p = 0.05; BDE-
153, p = 0.04). Interestingly, the only significant cor-
relation between serum and placenta BDE levels was
for BDE-47 (rs = 0.36, p = 0.009); correlations for
BDE-100 and BDE-153 were smaller and not statisti-
cally significant.
Thyroid hormones
Thyroid hormones were detected in 100% of the pla-
centa tissue samples. Descriptive statistics for the TH
measurements are provided in Table 1. T4 was measured
in the highest concentration with a geometric mean of
28.1 ng/g ww (range: 11.8–53.6 ng/g ww), followed by
Fig. 1 Geometric mean placenta BFR concentrations by infant sex. (* indicates p < 0.05; n = 94)
Table 1 Distribution or BFRs, THs and enzyme activity in placenta samples (n = 95)
Percentile
Variable MDL Detection Frequency (%) Geometric Mean Min 33rd 67th Max
PBDEs
BDE-47 0.07 91.2 5.45 0.12 2.81 10.5 140.5
BDE-99 0.07 68.6 2.02 0.16 1.35 3.47 222.8
BDE-100 0.02 88.2 1.56 0.06 0.86 3.02 50.1
BDE-153 0.01 93.1 2.23 0.07 1.69 3.38 513.2
BDE-154 0.01 83.3 0.64 0.01 0.44 1.07 20.2
BDE-209 0.17 52.9 3.08 0.25 1.94 5.19 50.4
ΣPBDEs 14.6 0.62 8.17 24.0 521.8
Phenolic compound
2,4,6-TBP 0.05 100 15.8 1.31 7.83 22.7 316.1
ΣBFRs 39.1 2.18 24.0 57.2 568.3
Thyroid hormones
T4 0.002 100 28.1 11.8 25.1 32.6 53.6
T3 0.002 100 0.37 0.10 0.32 0.45 0.84
rT3 0.002 100 2.64 0.73 2.19 3.25 7.59
Enzyme activity
DIO3 NA 100 0.74 0.01 0.58 1.12 3.86
3,3’-T2 SULT activity NA 100 3.32 0.35 2.34 4.59 19.2
T3 SULT activity NA 100 9.50 3.59 7.90 10.9 37.9
Brominated flame retardant concentrations (ng/g lipid), thyroid hormone levels (ng/g ww), DIO3 activity (pmol rT3/mg protein/min), 3,3’-T2 SULT activity (pmol
T2S/mg protein/min), and T3 SULT activity (fmol T3S/mg protein/min) measured in placenta tissue (n = 95). MDL indicates method detection limit. N = 95
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rT3 with a geometric mean of 2.64 ng/g ww (range:
0.73–7.59 ng/g ww), and T3 was measured in the low-
est concentrations with a geometric mean of 0.37 ng/g
ww (range: 0.10–0.84 ng/g ww). Levels of T4, T3, or
rT3 in placental samples did not differ by infant sex
(results not shown).
In analyses including all placental tissues (i.e. males
and females), BFRs were not correlated with placental
T3 or T4 concentrations. However, because we antici-
pated that the impact of BFRs on TH might vary by
infant sex, we examined associations stratified by sex.
Among males (n = 48), patterns of association were
negative between T3 and BDE-99, 2,4,6-TBP, and ΣBFRs;
although none were statistically significant. Conversely,
among females (n = 46), a positive association was ob-
served between T3 and BDE-99, 2,4,6-TBP, and ΣBFRs,
and, although not statistically significant, BDE-47, −153,
and ΣBDEs also showed a positive trend with T3. Data
suggest that T4 may be inversely correlated with BDE-
99 and BDE-100 among males; however, there was no
clear trend between T4 and BFR concentrations among
females. While concentrations of rT3 in placental tissue
were significantly inversely correlated with BDE-99 for
both males and females, a similar inverse association
between rT3 and BDE-209 was only observed among
males (rs = −0.35; p = 0.01; Table 2).
Adjusted regression analyses were also conducted to
assess associations between BFRs and THs while adjust-
ing for potential confounding by maternal age and gesta-
tional age at the time of delivery. As in correlation
analyses, none of the BFRs were significantly associated
with T3 in analyses including all participants. However,
although results generally did not reach statistical
significance, BDE-47, −99, and −100 were negatively
associated with T3 concentrations among males, while
BDE-47, −99, −100, −153 and 2,4,6-TBP were positively
associated with T3 among females. For example, among
males, those with the highest concentrations of BDE-99
in placenta had T3 levels 0.80 times those with the low-
est concentration of BDE-99 (95% confidence interval
(CI): 0.59, 1.07). Whereas females with the highest
concentrations of BDE-99 in placenta had T3 levels 1.50
times those with the lowest concentration of BDE-99
(95% CI: 1.10, 2.04). We observed little evidence of
associations between any of the BFR analytes and T4
concentrations; beta estimates were generally small, im-
precisely estimated, and not statistically significant.
These data are summarized in Fig. 2.
Among males, our results suggest that rT3 concentra-
tions may be inversely related to BDE-47, −99, −209,
and 2,4,6-TBP, with BDE-99 having the strongest associ-
ation in the highest tertile (10β = 0.72, CI: 0.51, 1.02). In
females, rT3 was generally inversely associated with
BDE-47, −99, −100, −153, and 2,4,6-TBP in the highest
tertiles, with BDE-99 having the strongest association
(10β = 0.68, CI: 0.50, 0.92).
DIO3 and SULT activities
DIO3 activity was measured in all placenta tissue mi-
crosome samples. The geometric mean value of DIO3
activity was 0.74 pmol rT3/mg protein/min, with a range
of 0.01–3.86 rT3/mg protein/min (RSD = 6.9%). Interest-
ingly, DIO3 activity was significantly higher (~1.8 times)
in placental tissues from male infants compared to
female infants (p < 0.01). DIO3 activity was negatively
correlated with T4 concentrations (rs = −0.21; p = 0.04);
however, Spearman correlations were small and were
not statistically significant between DIO3 activity and
other BFRs. In regression analyses, DIO3 activity among
males showed a suggestive positive association with
BDE-99, −100, and −153; however, no relationships were
statistically significant at the p < 0.05 level. In females,
Table 2 Spearman correlations between BFRs, thyroid hormones, and enzyme activity by infant sex
BDE-47 BDE-99 BDE-100 BDE-153 BDE-154 BDE-209 2,4,6-TBP ΣBFR ΣBDE T3 rT3 T4 DIO3 T2S
Males
(n = 48)
T3 −0.07 −0.21 −0.16 −0.03 −0.13 −0.10 −0.18 −0.22 −0.16 1.00
rT3 0.02 −0.34* 0.01 0.13 −0.04 −0.35* −0.02 −0.13 −0.11 0.14 1.00
T4 −0.14 −0.21 −0.21 0.04 −0.07 −0.15 −0.11 −0.16 −0.15 0.53* 0.35* 1.00
DI 0.03 0.16 0.15 0.04 −0.05 −0.02 0.00 0.05 0.09 −0.05 0.05 −0.27 1.00
T2S 0.02 −0.14 0.07 −0.01 0.02 −0.14 −0.02 −0.05 −0.01 −0.13 0.29* −0.15 0.11 1.00
T3S 0.29* 0.03 0.26# 0.27# 0.16 0.00 −0.11 −0.02 0.25# −0.15 0.10 −0.05 0.17 0.29
Females
(n = 46)
T3 0.22 0.33* 0.19 0.23 0.08 0.17 0.36* 0.35* 0.25# 1.00
rT3 −0.12 −0.34* −0.08 −0.10 −0.07 −0.05 −0.14 −0.13 −0.19 −0.16 1.00
T4 0.08 −0.07 −0.02 −0.03 −0.06 0.06 0.06 0.10 0.03 0.45* 0.24 1.00
DI 0.10 0.00 0.18 0.11 0.24# 0.22 0.02 0.08 0.09 −0.10 0.23 0.02 1.00
T2S 0.11 −0.06 0.05 0.13 0.11 −0.10 −0.11 0.02 0.13 −0.19 −0.08 −0.12 −0.16 1.00
T3S 0.08 −0.25# 0.11 0.15 0.15 −0.02 0.02 0.05 0.05 −0.07 −0.06 0.05 0.17 0.19
* < 0.05, # < 0.10
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DIO3 activity tended to be negatively associated in
the highest tertile for BDE-47, −99, −100, −153, and
2,4,6-TBP, with BDE-99 having the strongest association
(10β = 0.49, CI: 0.26, 0.91).
TH SULT activity was measured in all placenta tissue
cytosol samples. Both 3,3’-T2 and T3 SULT activities were
assessed in this study. The geometric mean value of 3,3’-T2
SULT activity was 3.32 pmol T2S/mg protein/min (range:
0.35–19.2 pmol T2S/mg protein/min; RSD= 5.7%), while
the geometric mean value of T3 SULT activity was 9.50
fmol T3S/mg protein/min (range: 3.59–37.9 fmol T3S/mg
protein/min; RSD = 6.8%). The 3,3’-T2 SULT enzyme activ-
ities were approximately one order of magnitude greater
than the T3 SULT activities, which was expected based on
their substrate preferences. 3,3’-T2 SULT activity was
significantly higher (~1.5 times) in placental tissues from fe-
males compared to males (p < 0.01). There was no observed
sex difference for T3 SULTactivity in placental tissues.
We observed a negative correlation between BDE-209
and 3,3’-T2 SULT activity (rs = −0.19; p = 0.06) in ana-
lyses using all samples, although the magnitude of the
correlation was small and not statistically significant.
3,3’-T2 SULT activity was not associated with other
BFRs. Among male infants, 3,3’-T2 SULT activity was
positively associated with rT3 (rs = 0.29; p = 0.04). In
combined analyses (males and females) T3 SULT activity
was not associated with any BFR analytes. However,
among males, T3 SULT activity was positively associated
with BDE-47 (rs = 0.29; p = 0.04) and showed positive,
but non-statistically significant associations with BDE-
100, −153, and ΣBDEs. There were no statistically
significant associations found in the female group;
however, there was a negative trend between BDE-99
and T3 SULT. Regression analyses produced similar
results. For example, T3 SULT activity among males was
positively associated with BDE-47, −100, and −153, with
BDE-153 having the strongest association (10β = 1.48, CI:
1.05, 2.09 comparing the 3rd to 1st tertile). As in correla-
tions analyses, T3S activity in females showed a negative
association with BDE-99 (10β = 0.67, CI: 0.49, 0.91) in
adjusted regression models.
Discussion
The goals of this study were to measure TH tissue
concentrations and endogenous TH DIO3 and SULT
activity in placenta tissue subsamples and to examine
their associations with BFRs. THs are essential to both
fetal and placental development. For example, THs are
important in trophoblast proliferation and migration
during placenta development, and restrictions on TH
delivery to the placenta can lead to several disorders of
the placenta [21]. In addition, maternal thyroid disorders
have been associated with pre-eclampsia, placental
abruption, and intra-uterine growth restriction (IUGR)
[32–35]. Therefore, understanding environmental stressors
that may affect thyroid regulation in the placenta is of
critical importance.
To our knowledge, this is the first study to measure
T4, T3, and rT3 in human placental tissues using liquid
chromatography tandem mass spectrometry (LC/MS-
Fig. 2 Multiplicative change in T3 and rT3 concentrations measured in placenta separated by tertile of each BFR. Analyses are adjusted for
gestational age and maternal age. Horizontal bars reflect the 95% CI and * indicates p < 0.05
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MS), and the first study to measure 3,3’-T2/T3 SULT
activity in human placental tissues. The use of LC-MS/
MS offers greater specificity and sensitivity over RIA-
based methods [30]. To our knowledge, THs have only
been measured in placenta in one previous study in a
cohort of 16 women with normal pregnancies using an
RIA-based method. This study reported values for T4,
T3, and rT3 (18.8, 0.03, and 1.70 ng/g tissue, respectively)
[24], similar to levels reported here. Serum T4/T3 ratios
are widely used in the clinical setting to evaluate TH status
in individuals; however, the measurement of THs in spe-
cific tissues is not widely used, and there is not much
known about the TH status of specific tissues such as the
placenta, nor how it changes during pregnancy.
In general, our results suggest that the concentrations
of BFRs in the placenta may be associated with lower
levels of rT3. Associations were also observed for T3,
but differed by sex (negative associations for males and
positive associations for females). Although PBDEs were
not measured in placenta in past studies, previous preg-
nancy studies have reported positive, negative, and no
associations between serum PBDE and TH concentra-
tions. For example, in a recent study by Abdelouahab et
al., PBDEs and THs were measured in maternal blood
and umbilical cord blood at two different time points
during gestation [36]. That study observed negative
associations between PBDEs and Total T4 (TT4) and
Total T3 (TT3), as well as positive associations between
PBDEs and free T4 and free T3 in maternal serum
collected at less than 20 weeks gestation. However, these
associations reversed for free T4 and free T3 in maternal
blood collected at the time of delivery [36]. A 2010 study
by Stapleton et al. observed positive associations be-
tween PBDEs and TT3, TT4, and free T4 in maternal
blood samples collected during the third trimester [27].
Finally, several studies have reported no associations
between PBDEs and THs measured in maternal serum
samples collected during the second trimester, collected
at delivery, or in umbilical cord blood [37–39]. Past
studies and our own work may not be directly compar-
able due to differences in their experimental designs and
methods. Additionally, inter-individual variability in TH
set-points around which TH homeostasis operates may
contribute variability to these studies. These differences
are magnified during pregnancy, and this contributes to
the difficulty in determining a normal TH profile for a
pregnant mother (serum concentrations), and perhaps
within the placenta tissue itself [40].
We observed statistically significant negative associa-
tions between rT3 and BDE-99 tissue concentrations in
all samples. rT3 is the genomically inactive form of TH
that is formed from the inner ring deiodination (IRD) of
T4 by type 1 DIO (DIO1) or DIO3. DIO3 is one of three
DIO enzyme isoforms that only performs IRD. The
placenta exhibits high DIO3 expression in early preg-
nancy, and total DIO3 activity increases significantly
throughout gestation until birth [41]. It is thought that
DIO3 plays an important role in buffering the maternal
supply of T4 within the placental tissue compartment
before being transported to fetal circulation, as well as
provides a source of iodide for the fetus via deiodination
[21, 22]. As a result, DIO enzyme inhibition by environ-
mental contaminants such as PBDEs and their metabo-
lites may lead to reductions in T4 deiodination, causing
higher levels of T4 and lower levels of rT3 in placental
tissues. Such inhibition, particularly by BDE-99, has been
shown using in vitro models with human liver cytosol
and human glial cells [12, 42]. This mechanism may
contribute to the observations in this study, as higher
concentrations of BDE-99 were associated with lower
DIO3 activity and lower concentrations of rT3 among
females. However, among males, we observed inverse
trends between BDE-99 and rT3 in the absence of an
impact on DIO3, suggesting an alternate mechanism of
action between BDE-99 and rT3.
Our current work is the first to evaluate TH SULT
activity in human placental tissues. We chose to evaluate
SULT activity because in vitro work from our laboratory
using pooled human liver cytosol indicated that TH
SULT enzymes are more sensitive to inhibition by BFRs
compared to DIO activity [11]. However, 3,3’-T2 SULT
activity did not show any statistically significant associa-
tions with BFRs. The variability in 3,3’-T2 SULT activity
amongst males is much higher than among females and
may provide some insight into the sex differences in
placental SULT expression and activity.
T3 SULT activity was also measured in the samples.
The T3 SULT enzyme activity rates in this study were a
full order of magnitude lower than that of 3,3’-T2. These
results are consistent with other studies that have com-
pared the sulfation rates of the different iodothyronines
in various tissues types, with 3,3’-T2 being the preferred
substrate for sulfation and having an activity rate 1–2
orders of magnitude greater than T3 [43–45]. As such,
3,3’-T2 is used as a surrogate model for T3 sulfation
kinetics in in vitro experiments [46]. The positive associ-
ation between 3,3’-T2 and T3 SULT activity observed
here supports this claim. However, T3 sulfation plays a
greater biological role in regulating the available pool of
T3 for subsequent binding to thyroid receptors [47].
Sulfation of T3 is a reversible reaction that inactivates
the biological activity of T3 and is thought to create a
reservoir of T3 that can be reactivated following
hydrolysis by arylsulfatases in a tissue-specific manner
[21]. This metabolic pathway is a potentially important
step for buffering the concentrations of T3 in the pla-
centa before delivery to the fetal compartment. In this
study, T3 SULT enzyme activities showed a significantly
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positive association with BDE-47 in males (rs = 0.29,
p = 0.04), and a suggestive negative association with
BDE-99 in females (rs = −0.25, p = 0.09). Additionally, we
observed a positive association for the highest tertile of
BDE-153 exposure in males (10β = 1.48, p = 0.03), and a
negative association in the highest tertile of BDE-99
exposure in females (10β = 0.67, p = 0.01) in our adjusted
models. This may suggest that BDE-99 is inhibiting T3
sulfation in placental tissues and leading to an increase in
T3; however, it is unclear why this was only observed in
placental tissues from females.
One interesting finding from this study is that BFR
levels in placenta, and their associated impacts, may be
dependent upon infant sex. Despite seeing no difference
in maternal serum levels, BFR levels in placenta were
higher in placenta samples associated with males. The
underlying mechanisms of these sex-specific differences
are not known at this time; however, the sex of the
infant seems to play a role in the bioaccumulation
potential, metabolism, and/ or kinetic parameters of the
placenta during pregnancy. It is possible that the sex-
specific differences in placental morphology and func-
tion may play a role in this organ’s ability to accumulate
and metabolize BFRs [48]. While other studies have
examined PBDE accumulation in placental tissues, no
studies to date have identified differences based on in-
fant sex. This may be due to the smaller sample size of
these studies, which were generally less than 50 samples,
or due to the fact that they were conducted in regions
where use and exposure to PBDEs was lower than in the
U.S. (e.g. Europe). Initially it was suspected that differ-
ences in lipid content between male and female placen-
tae were driving differences in bioaccumulation of BFR
compounds; however, there were no observed differ-
ences in tissue total lipid content between sexes. It is still
possible that fine-scale differences in the lipid profiles
between sexes may be driving these observed BFR bio-
accumulation rates, and future research should utilize a
lipidomic assessment of placenta tissue in order to fully
characterize the lipid molecule profile of placental tis-
sues. This is important because PBDEs have been shown
to differentially bind to various classes of lipoproteins,
and there may exist sex differences in the expression
of placenta lipoproteins [49, 50]. One additional ex-
planation of differences in BFR bioaccumulation rates
may be that the placental tissue expression of TH
transporting membrane proteins, including monocar-
boxylate transporters (MCTs), System-L amino acid
transporters (LATs), and organic-anionic transport
protein (OATPs), is sexually dimorphic. Higher ex-
pression levels of these transporter proteins in male
placentae may lead to higher rates of transport of TH-
like compounds such as PBDEs and consequently,
higher tissue concentrations [51, 52].
This is also the first study to compare placental tissue
concentrations of THs with BFR concentrations in a
human cohort, as well as one of the first to measure
placental tissue DIO3 and SULT activity. THs are trans-
ported in the blood bound to transport proteins such as
TTR and TBG before uptake into cells in peripheral tis-
sues via TH transport proteins such as MCTs, LATs, and
OATPs [53]. However, little is known about the tissue
concentrations of THs after uptake and subsequent
metabolism by DIOs or SULTs. The tissue concentra-
tions of THs are important in facilitating TH-mediated
genomic activity, and in the case of the placenta, import-
ant in regulating the maternal supply of THs to fetal cir-
culation to support growth. The results of this study
indicate that placental TH concentrations may be sensitive
to BFR tissue concentrations in a sex-specific manner, and
may have possible downstream effects on TH-mediated
developmental processes throughout gestation.
A limitation of this study is the nature of the placenta
tissue subsamples. First, the tissues may not have been
consistently harvested from the same sections of the
organ following delivery. This means that some tissue
subsamples may have been taken from the peripheral
sections of the placenta, while others may have been
taken from more central locations. Due to the heteroge-
neous nature of the placenta, as well as spatial differ-
ences in cell type, vasculature, and lipid content of the
organ, the samples analyzed in this study may not be
equally representative. Although we measured BFRs,
THs and enzyme activity in 95 samples, our analyses
were also limited by our relatively small sample size
which may have reduced our statistical ability to detect
meaningful associations, particularly after stratification.
In addition, we evaluated the impact of several potential
confounding variables in assessing associations; nonethe-
less, it is possible that our results may be explained by
residual confounding by other unmeasured variables;
however, our cohort was relatively homogeneous, with
the majority of the women reporting African American
race and low educational attainment. While this may
reduce the potential for confounding bias it could also
limit the generalizability of our findings to other study
populations. In addition, a comparison of maternal TH
levels and placenta levels would be of great interest.
Unfortunately we did not have paired maternal samples
with TH measurements for women in our cohort and we
were unable to evaluate relationships; however, future
studies should consider including a comparison of TH
measurements between the maternal and placental
compartments. Additionally, future studies should evalu-
ate TH concentrations, as well as other TH-related end-
points within the placenta tissue in order to broaden
our understanding of BFR effects on TH homeostasis
during pregnancy.
Leonetti et al. Environmental Health  (2016) 15:113 Page 8 of 10
Conclusions
Cumulatively, our research suggests BFRs accumulate in
the placenta, and may be associated with TH changes in a
sex-specific manner. More research is needed to elucidate
the effects of BFRs within placenta during pregnancy, as
well as the mechanisms of action and biological conse-
quences of exposure; however, our results provide a pos-
sible mechanism to support sex-differences reported for
the impacts of environmental exposure on children’s
growth and development.
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